Radiolabeled hydroxamate-based matrix metalloproteinase inhibitors: How chemical modifications affect pharmacokinetics and metabolic stability
- 1 July 2016
- journal article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 43 (7) , 424-437
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Roles of matrix metalloproteinases in cancer progression and their pharmacological targetingThe FEBS Journal, 2010
- Matrix Metalloproteinases: Regulators of the Tumor MicroenvironmentCell, 2010
- To bind zinc or not to bind zinc: An examination of innovative approaches to improved metalloproteinase inhibitionBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2010
- Molecular Targets of Rheumatoid ArthritisInflammation & Allergy - Drug Targets, 2008
- Matrix Metalloproteinase-9/Gelatinase B is a Putative Therapeutic Target of Chronic Obstructive Pulmonary Disease and Multiple SclerosisCurrent Pharmaceutical Biotechnology, 2008
- Mechanisms to Inhibit Matrix Metalloproteinase Activity: Where are we in the Development of Clinically Relevant Inhibitors?Recent Patents on Anti-Cancer Drug Discovery, 2007
- Recent advances in MMP inhibitor designCancer and Metastasis Reviews, 2006
- MMPs - Role in Cardiovascular Development and DiseaseFrontiers in Bioscience-Landmark, 2006
- Matrix metalloproteinases: roles in cancer and metastasisFrontiers in Bioscience-Landmark, 2006
- Design and Therapeutic Application of Matrix Metalloproteinase InhibitorsChemical Reviews, 1999